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BACKGROUND: Standard administration of newer oral P2Y12 inhibitors, 
including prasugrel or ticagrelor, provides suboptimal early inhibition of 
platelet aggregation (IPA) in patients with ST-segment–elevation myocardial 
infarction undergoing primary percutaneous coronary intervention. We aimed 
to investigate the effects of cangrelor, tirofiban, and prasugrel, administered 
as chewed or integral loading dose, on IPA in patients undergoing primary 
percutaneous coronary intervention.
METHODS: The FABOLUS-FASTER trial (Facilitation Through Aggrastat or 
Cangrelor Bolus and Infusion Over Prasugrel: A Multicenter Randomized 
Open-Label Trial in Patients with ST-Elevation Myocardial Infarction Referred 
for Primary Percutaneous Intervention) is an investigator-initiated, multicenter, 
open-label, randomized study. A total of 122 P2Y12-naive patients with ST-
segment–elevation myocardial infarction were randomly allocated (1:1:1) to 
cangrelor (n=40), tirofiban (n=40) (both administered as bolus and 2-hour 
infusion followed by 60 mg of prasugrel), or 60-mg loading dose of prasugrel 
(n=42). The latter group underwent an immediate 1:1 subrandomization 
to chewed (n=21) or integral (n=21) tablets administration. The trial was 
powered to test 3 hypotheses (noninferiority of cangrelor compared with 
tirofiban using a noninferiority margin of 9%, superiority of both tirofiban 
and cangrelor compared with chewed prasugrel, and superiority of chewed 
prasugrel as compared with integral prasugrel, each with α=0.016 for 
the primary end point, which was 30-minute IPA at light transmittance 
aggregometry in response to 20 μmol/L adenosine diphosphate.
RESULTS: At 30 minutes, cangrelor did not satisfy noninferiority compared with 
tirofiban, which yielded superior IPA over cangrelor (95.0±8.9 versus 34.1±22.5; 
P<0.001). Cangrelor or tirofiban were both superior to chewed prasugrel (IPA, 
10.5±11.0; P<0.001 for both comparisons), which did not provide higher IPA 
over integral prasugrel (6.3±11.4; P=0.47), despite yielding higher prasugrel 
active metabolite concentration (ng/mL; 62.3±82.6 versus 17.1±43.5; P=0.016).
CONCLUSIONS: Cangrelor provided inferior IPA compared with tirofiban; 
both treatments yielded greater IPA compared with chewed prasugrel, which 
led to higher active metabolite concentration but not greater IPA compared 
with integral prasugrel.
REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: 
NCT02978040; URL: https://www.clinicaltrialsregister.eu; EudraCT 2017-
001065-24.
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Antithrombotic therapy, including oral or paren-teral antiplatelet and anticoagulation agents, or both, mitigates the ischemic risks in patients with 
ST-segment–elevation myocardial infarction (STEMI) un-
dergoing primary percutaneous coronary intervention 
(PCI).1–4 New-generation oral inhibitors of adenosine 
diphosphate (ADP)–activated platelet P2Y12 receptor 
(prasugrel or ticagrelor) are recommended, but their 
administration does not abrogate high residual platelet 
reactivity (HRPR) up to 4 or 6 hours after standard load-
ing dose.5–7 Strategies to increase the bioavailability of 
oral P2Y12 inhibitors, such as crushing or chewing tab-
lets, have been investigated, but pharmacokinetic and 
pharmacodynamic data remain limited.8–11 Parenteral 
antiplatelet agents, including tirofiban or cangrelor, 
have been shown to provide more rapid and sustained 
inhibition of platelet aggregation (IPA) as compared 
with prasugrel or ticagrelor. Pharmacodynamic data on 
cangrelor showed that it is able to achieve very high 
degrees (>80%) of platelet inhibition,12 suggesting that 
its effect could be equivalent to that of tirofiban; how-
ever, no comparative data on IPA are available between 
tirofiban or cangrelor in patients undergoing primary 
PCI, and it remains unclear how these treatment op-
tions compare with chewed prasugrel instead of stan-
dard administration of integral tablets.
We conducted the FABOLUS-FASTER trial (Facilita-
tion Through Aggrastat or Cangrelor Bolus and Infusion 
Over Prasugrel: A Multicenter Randomized Open-Label 
Trial in Patients with ST-Elevation Myocardial Infarction 
Referred for Primary Percutaneous Intervention) to in-
vestigate the acute pharmacodynamic effects of can-
grelor, tirofiban, or prasugrel, administered at standard 
60 mg loading dose as integral or chewed tablets, in 
patients with STEMI undergoing primary PCI.
METHODS
Study Design and Patient Population
The FABOLUS-FASTER trial (URL: https://www.clinicaltrials.
gov; Unique identifier: NCT02978040; URL: https://www.
clinicaltrialsregister.eu; EudraCT 2017-001065-24) is an inves-
tigator-initiated, multicenter, open-label, randomized trial.
The study rationale and design have been reported previ-
ously.13 Briefly, patients with suspected STEMI arriving to the 
catheterization laboratory with indication for coronary angi-
ography were screened for eligibility. After informed consent 
was obtained, and coronary angiography confirmed the diag-
nosis, P2Y12-naive patients undergoing primary PCI (within 
12 hours, or 24 hours if ongoing ischemia was demon-
strated) were enrolled at 3 centers (Bern University Hospital, 
Switzerland; University Hospital Federico II, Naples, Italy; and 
University Hospital of Ferrara, Italy). The main exclusion cri-
teria were inability to provide informed consent or to adhere 
with study protocols (prasugrel pills chewing or ingestion); 
contraindications or known hypersensitivity or allergy to aspi-
rin, prasugrel, intravenous unfractionated heparin (UFH), can-
grelor, or tirofiban; contraindications to the PCI procedure; 
recent (<7 days) treatment with study drugs (glycoprotein IIb/
IIIa inhibitor [GPI] or P2Y12 inhibitors or cangrelor); dialysis; 
recent (<15 days) or ongoing major bleeding; recent (<15 
days) major surgery; fibrinolytics administration (<30 days); 
oral anticoagulation therapy; prior stroke or transient isch-
emic attack; concomitant disease affecting life expectancy 
(<6 months); pregnant or breastfeeding; and recent (<30 
days) recruitment in alternative trials on investigational drugs.
Patients were randomly allocated (1:1:1) to standard 
regimen of tirofiban (bolus + 2-hour infusion, followed by 
60 mg loading dose prasugrel at the infusion discontinu-
ation time), standard regimen of cangrelor (bolus + 2-hour 
infusion, followed by 60 mg loading dose prasugrel at the 
infusion discontinuation time), or prasugrel 60 mg (integral 
or chewed tablets) at PCI initiation. Patients in the prasugrel 
Clinical Perspective
What Is New?
• The FABOLUS-FASTER trial (Facilitation Through 
Aggrastat or Cangrelor Bolus and Infusion Over Pra-
sugrel: A Multicenter Randomized Open-Label Trial 
in Patients with ST-Elevation Myocardial Infarction 
Referred for Primary Percutaneous Intervention) is 
the first study comparing the pharmacodynamic 
effects of cangrelor, a direct parenteral P2Y12 inhib-
itor, with tirofiban, a glycoprotein IIb/IIIa inhibitor, 
as well as the pharmacodynamic and pharmaco-
kinetic effects of a 60-mg chewed or integral pill 
intake of prasugrel, an oral indirect P2Y12 inhibitor 
among patients with ST-segment–elevation myo-
cardial infarction undergoing primary percutane-
ous coronary intervention.
• Cangrelor did not reach noninferiority with tirofi-
ban at adenosine diphosphate–induced platelet 
aggregation; the latter showed superior platelet 
inhibition at 30 minutes as well as at all other time 
points.
• Chewed prasugrel led to higher active metabolite 
concentration but not greater inhibition of platelet 
aggregation compared with integral prasugrel.
What Are the Clinical Implications?
• This study supports the use of parenteral drugs to 
achieve immediate inhibition of platelet aggrega-
tion and to bridge the initial gap in platelet inhibi-
tion observed with oral P2Y12 inhibitors.
• Cangrelor, unlike tirofiban, was associated with 
modest reductions of platelet reactivity during the 
drug infusion and during the transition toward oral 
P2Y12 inhibitors.
• Tirofiban, by exerting more potent and consistent 
inhibition of platelet aggregation, may be more 
effective than cangrelor in reducing the risks of 
acute ischemic complications, which need to be 
ascertained in the context of studies powered for 
clinical end points.
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group immediately underwent a subrandomization (1:1) to 
chewed or integral tablets of prasugrel oral loading dose. 
Randomization was concealed and stratified according to 
center and to time from symptom onset to PCI (<3 hours, 
3 to 6 hours, >6 hours) with randomly alternating blocks of 
3 or 6 in the first randomization, and stratified according to 
center with randomly alternating blocks of 2 or 4 in the sec-
ond randomization. The electronic data capture system deliv-
ered by AdvicePharma was used. The study complied with the 
Declaration of Helsinki and Good Clinical Practice and was 
approved by national agencies and local ethics committees. 
Further details are reported in the Data Supplement.
The data that support the findings of this study are avail-
able from the corresponding author on reasonable request.
Medications and Procedures
Aspirin was administered to all patients before primary PCI 
(150 to 300 mg orally or 80 to 150 mg intravenously, then 
81 to 325 mg daily). Tirofiban was administered at a 25 µg/
kg bolus + 0.15 µg/kg per minute infusion for 2 hours (or 
infusion at 0.075 µg/kg per minute if creatinine clearance was 
<30 mL/min). Cangrelor was administered at a 30 µg/kg bolus 
+ 4 µg/kg per minute infusion for 2 hours. In both tirofiban 
and cangrelor arms, patients received integral pills of 60 mg 
loading dose prasugrel at the time of infusion discontinuation 
with a following maintenance dose of 10 mg daily (5 mg daily 
if body weight <60 kg or age >75 years). Patients in the pra-
sugrel group had not to have received parenteral antiplatelet 
agents and received prasugrel (integral or chewed) at an iden-
tical loading dose of 60 mg, with a following maintenance 
dose of 10 mg daily (5 mg daily if body weight <60 kg or age 
>75 years). Patients in the chewed prasugrel group had to 
chew prasugrel tablets for at least 10 to 15 seconds and then 
swallow with water (≈150 mL) as described.10
UFH was used as an anticoagulant with an initial bolus of 
50 to 70 UI/kg in tirofiban- and cangrelor-treated patients or 
70 to 100 UI/kg bolus in prasugrel-treated patients, eventu-
ally followed by further boluses to reach an intraprocedural 
activated clotting time of at least 250 seconds. Protocol rec-
ommended to stop UFH at the end of PCI in the absence of 
strict clinical indications.
Blood samples were collected before study drug initiation 
(baseline), as well as at 15 minutes, 30 minutes, 1 hour, 2 
hours, 3 hours, and between 4 and 6 hours after study drug 
administration (bolus completion or oral pills ingestion).
Pharmacodynamic and Pharmacokinetic 
Assessment
Pharmacodynamic assessments were performed using light 
transmittance aggregometry (LTA).14 Blood samples were col-
lected in sodium citrate anticoagulated tubes. Platelet-rich 
plasma was stimulated with 5 and 20 μmol/L ADP and 5 and 
15 μmol/L thrombin receptor agonist peptide (TRAP). Platelet 
aggregation (maximal percent of platelet aggregation after 
agonist stimulation) was collected and used to calculate IPA.7 
The percent of late platelet aggregation was also collected.
Multiple electrode aggregometry (Multiplate, Roche 
Diagnostics, Switzerland) was also performed at 2 centers 
(Bern and Naples).15 Whole blood samples were collected in 
hirudin-anticoagulated tubes, then diluted with saline (1:2 
with 0.9% NaCl) and stimulated with agonists (ADP or TRAP), 
and platelet aggregation was recorded continuously for 6 
minutes. The area under the aggregation curve (AUC) value 
was used to express platelet inhibition.
A pharmacokinetic assessment was implemented within 
the prasugrel arm after 10 patients had already been included 
on request from the Italian Medicines Agency to compare 
integral versus chewed prasugrel. Prasugrel active metabolite 
(PAM) was measured at each time point by using precooled 
ethylenediaminetetraacetic acid tubes treated with 25 μL of 
500 mM 3′-methoxyphenacyl bromide in acetonitrile within 
30 seconds after collection to derivatize and stabilize the PAM 
as described previously.9,16 Plasma samples were centrifuged 
(2800 rpm for 15 minutes at 4°C) within 30 minutes and 
stored in polypropylene tubes at −20°C/−80°C. The analysis 
was performed at a central laboratory (University Hospital of 
Verona) through validated liquid chromatography methods 
and tandem mass spectrometric detection.
Study End Points
The primary end point was the 30-minute percentage of IPA 
(%IPA) assessed with LTA after stimulation of platelet-rich 
plasma with ADP 20 µmol/L. %IPA is defined as follows: 
100% × (Baseline Platelet Aggregation − Platelet Aggregation 
at Time t)/Baseline Platelet Aggregation.
Secondary end points were LTA %IPA after TRAP (5 and 
15 µmol/L), ADP (5 µmol/L) stimulation at all time frames, and 
ADP (20 µmol/L) at 15 minutes, 1 hour, 2 hours, 3 hours, and 
4 to 6 hours.
Additional secondary end points were AUC values (resid-
ual platelet reactivity) measured by Multiplate after stimula-
tion with ADP and TRAP at all time points.
HRPR was defined as percent of patients with platelet reac-
tivity >59% after ADP 20 µmol/L or >46% after ADP 5 µmol/L 
or >46 U at Multiplate ADPtest as described previously.14,17,18
For pharmacokinetic assessment, the time to maximum 
plasma concentration, maximum observed plasma concen-
tration, and the area under the plasma concentration ver-
sus time curve from time 0 to various times (AUC0 to 30 minutes, 
AUC0 to 1 hour, AUC0 to 2 hours, AUC0 to 4 hours) were analyzed.
Adverse clinical outcomes within 30 days were collected 
including all-cause mortality, cardiovascular mortality, myocar-
dial infarction (MI), stroke, transient ischemic attack, definite 
or probable stent thrombosis, urgent target vessel revas-
cularization, unplanned revascularization, bleeding occur-
rences, and net adverse clinical events. Events were blindly 
adjudicated by an independent clinical event committee. All 
deaths were categorized as cardiovascular or noncardiovas-
cular. Cardiovascular death was defined as death resulting 
from an acute MI, sudden cardiac death, death from heart 
failure, death from stroke, death (immediate) from cardiovas-
cular procedures, death from cardiovascular hemorrhage, and 
death from other cardiovascular causes. Noncardiovascular 
death was defined as any death not thought to be from a 
cardiovascular cause. MI was defined according to the fourth 
universal definition of MI.19 Stroke, categorized as ischemic or 
hemorrhagic or unknown, was defined as an acute episode 
of focal or global neurologic dysfunction caused by central 
nervous system (brain, spinal cord, and retina) vascular injury 
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as a result of hemorrhage or infarction. Transient ischemic 
attack was defined as a new transient episode of neurologic 
dysfunction (usually 1 to 2 hours), always within 24 hours, 
caused by focal brain, spinal cord, or retinal ischemia, with-
out acute infarction. Stent thrombosis was defined according 
to the Academic Research Consortium.20 Urgent target vessel 
revascularization was defined as an urgent coronary revas-
cularization in a target coronary vessel (ie, a vessel treated 
during the index PCI), and unplanned revascularization as 
any revascularization that was not prespecified or staged 
after index PCI. Bleeding events were defined according to 
BARC (Bleeding Academic Research Consortium),21 TIMI 
(Thrombolysis in Myocardial Infarction),22 and GUSTO (Global 
Utilization of Streptokinase and Tissue Plasminogen Activator 
for Occluded Arteries)23 classifications. Net adverse clinical 
events were defined as the composite of death, nonfatal MI, 
definite or probable stent thrombosis, nonfatal stroke, and 
BARC 2, 3, or 5 bleeding.
Statistical Analysis
All analyses were performed at the Clinical Trials Unit of Bern 
according to the prespecified statistical analysis plan. The 
sample size calculation was based on testing the noninferior-
ity of cangrelor compared with tirofiban, superiority of both 
tirofiban and cangrelor compared with chewed prasugrel, 
and superiority of chewed compared with integral prasugrel.
The sample size estimation, which is partly based on pre-
vious evidence,7 followed these considerations (3 primary 
end points, each with α of 0.05/3=0.016): assuming at least 
94% IPA with ADP 20 μmol/L 30 minutes after parenteral 
drug administration, 8% as SD, 9% as noninferiority margin 
(this margin was considered a clinically meaningful reduc-
tion in the %IPA to refute noninferiority), and 0.016 α, 40 
patients per arm would provide a power of 99% to demon-
strate noninferiority of cangrelor compared with tirofiban. If 
noninferiority of cangrelor was not met, then the superiority 
of tirofiban over cangrelor was tested (prespecified second-
ary end point); assuming 55% IPA with ADP 20 μmol/L 30 
minutes after chewed prasugrel, a 24% SD, and 0.016 as 
α, the study power would be 100% to demonstrate supe-
riority of tirofiban (n=40) compared with chewed prasugrel 
(n=20) and superiority of cangrelor (n=40) compared with 
chewed prasugrel (n=20); and assuming 55% IPA with ADP 
20 μmol/L 30 minutes after chewed prasugrel, a 24% SD, 
and 0.016 as α, 20 patients per arm would provide a power 
of 82% to demonstrate superiority of chewed compared 
with integral prasugrel.
Clinical characteristics, procedural data, and medication 
use were summarized using means with SDs and counts with 
percentages, P values from t tests, Fisher exact tests, and χ2 
tests. Pairwise mean differences in platelet inhibition (differ-
ence in %IPA) with 95% CIs were calculated (cangrelor versus 
tirofiban, cangrelor versus chewed prasugrel, tirofiban versus 
chewed prasugrel, chewed versus integral prasugrel; based on 
generalized mixed models, including data on all time points 
after drug administration, and random effects of patient as 
appropriate), and a z test was used to test noninferiority. 
Generalized mixed models (including data on all time points 
after drug administration) were used to test superiority (%IPA 
at LTA or AUC unit on Multiplate, as continuous variables or 
random effects of patient, as appropriate). P values are inter-
preted with a Bonferroni post hoc correction. Generalized 
mixed models used the appropriate link function according 
to the type of primary or secondary outcomes measured (con-
tinuous or binary) and adjusted for time point (minutes to 
hours after drug administration) and the interaction between 
randomized arm and time point, with random effects added 
of site and patient as appropriate. Wald χ2 test was used to 
compare event rates. Hazard ratios were estimated by fitting 
a Cox proportional hazards model (proportional hazards were 
tested and nonsignificant). The α used to claim statistical sig-
nificance is 0.016 for the primary end point. Secondary end 
points were analyzed with a 2-sided α set at 0.05 to allow 
conventional interpretation of results. Statistical analyses 
were performed with Stata version 16.1.
RESULTS
Between July 4, 2017, and August 26, 2019, we en-
rolled 122 patients with STEMI intended for primary 
PCI (cangrelor, n=40; tirofiban, n=40; prasugrel, n=42 
[chewed, n=21; integral, n=21]) across 3 centers in 
Switzerland and Italy. Patient disposition is summa-
rized in Figure 1.
Baseline and procedural characteristics were well 
balanced across groups (Tables  1 and 2 and Tables I 
and II in the Data Supplement). Patients were predomi-
nantly male (76%), mean age was 64 years, 20% had 
diabetes mellitus, and 52% presented within 3 hours 
from symptom onset. Most patients presented in sinus 
rhythm, 27% had Killip class >1, 4% previously had 
cardiac arrest, and 4% required continuous infusion of 
vasopressors. Also, 21 (17%) patients were on chronic 
aspirin at the time of presentation and 115 (94%) re-
ceived aspirin loading dose, administered mainly intra-
venously, whereas all patients received UFH. The radial 
was the primarily attempted access site in 84% of the 
patients, and 98% of the patients had TIMI flow 3 at 
the end of the procedure. Clinical outcomes at 30 days 
are shown in Table III in the Data Supplement.
Pharmacodynamic Assessment
Light Transmittance Aggregometry
At baseline, there were no differences across groups 
in ADP- or TRAP-induced platelet aggregation. Fig-
ure 2 and Table IV in the Data Supplement show IPA 
with LTA ADP 20 µmol/L. At 30 minutes, cangrelor did 
not reach noninferiority with tirofiban, which, in turn, 
achieved superior IPA over cangrelor (IPA, 95.0±9.0 ver-
sus 34.1±22.5; P<0.001), cangrelor or tirofiban were 
both superior to chewed prasugrel (IPA, 10.5±11.0; 
P<0.001 for both comparisons), and chewed prasug-
rel did not reach superior IPA over integral prasugrel 
(6.3±11.4; P=0.47). At secondary analyses, tirofiban 
provided greater IPA at all time points compared with 
cangrelor or chewed prasugrel. Cangrelor provided 
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greater IPA up to 1 hour compared with chewed pra-
sugrel, but IPA did not differ at 2 hours and it became 
higher with chewed prasugrel compared with cangrelor 
at 3 and 4 to 6 hours. The proportions of patients with 
IPA >80% or 90% were consistently higher with tiro-
fiban compared with cangrelor or chewed or integral 
prasugrel (Figure 2B and 2C). No patient with tirofiban 
had HRPR within the first 2 hours, whereas HRPR rates 
ranged from 50% to 58% during cangrelor infusion 
(Figure 3 and Table V in the Data Supplement). Can-
grelor, in turn, provided significantly lower HRPR rates 
compared with chewed prasugrel at 15 and 30 min-
utes but not at 1 and 2 hours; at 3 hours and 4 to 
6 hours, chewed prasugrel was associated with lower 
HRPR rates compared with cangrelor. HRPR rates trend-
ed lower with chewed versus integral prasugrel for up 
to 2 hours without reaching statistical significance. The 
primary end point for chewed versus integral prasugrel 
remained consistent when stratified by patients receiv-
ing opioids or not (Pinteraction=0.226; Table VI in the Data 
Supplement).
The kinetics of platelet inhibition were consistent af-
ter 5 µmol/L ADP (Figure 4A and Tables V and VII in the 
Data Supplement).
Tirofiban was also associated with higher inhibition 
of 15 or 5 µmol/L TRAP-induced platelet aggregation 
at all time points compared with cangrelor or chewed 
prasugrel (Figure 4B and 4C and Table VII in the Data 
Supplement). IPA after 15 µmol/L TRAP was higher 
with cangrelor compared with chewed prasugrel at 15 
minutes but not thereafter up to 2 hours, whereas at 
3 and 4 to 6 hours chewed prasugrel was associated 
with greater IPA as compared with cangrelor. IPA after 
5 µmol/L TRAP did not differ between cangrelor and 
chewed prasugrel up to 3 hours but was greater in the 
latter group at the 4 to 6 hours assessment.
Results remained consistent when the 2 prasugrel 
arms were analyzed as a single group against tirofiban 
or cangrelor or when IPA was calculated using late in-
stead of maximal aggregation.
Multiplate
ADP-induced platelet aggregation was lower in tiro-
fiban-treated patients compared with cangrelor or 
chewed prasugrel up to 2 hours, and in turn lower with 
cangrelor compared with chewed prasugrel from 15 
minutes to 2 hours, but higher thereafter with cangre-
lor compared with chewed or integral prasugrel (Figure 
Figure 1. Flow chart of the FABOLUS-FASTER trial.
*For 2 hours or to the end of the PCI. FABOLUS-FASTER indicates Facilitation Through Aggrastat or Cangrelor Bolus and Infusion Over Prasugrel: A Multicenter 
Randomized Open-Label Trial in Patients with ST-Elevation Myocardial Infarction Referred for Primary Percutaneous Intervention; PCI, percutaneous coronary inter-
vention; and STEMI, ST-segment–elevation myocardial infarction.
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I and Table VII in the Data Supplement). Chewed pra-
sugrel was associated with lower platelet aggregation 
than integral prasugrel at 30 minutes and 1 hour. Tiro-
fiban was associated with higher TRAP-induced platelet 
aggregation compared with cangrelor or chewed prasu-
grel (P<0.001 at any time point for both comparisons) 
whereas there was no difference between cangrelor and 
chewed prasugrel or between the 2 prasugrel groups.
Table 1. Baseline Clinical Characteristics
Variable Cangrelor (n=40) Tirofiban (n=40) Chewed Prasugrel (n=21) Integral Prasugrel (n=21)
Age, y 65.6±12.2 62.9±13.0 64.7±11.7 60.6±10.8
Male sex 29 (73) 31 (78) 19 (90) 14 (67)
Body mass index, kg/m2 27.2±4.7 27.7±4.3 27.4±5.2 26.5±3.2
Diabetes mellitus 7 (18) 9 (23) 3 (14) 5 (24)
  Oral treated 5 (71) 5 (56) 3 (100) 3 (60)
  Insulin treated 0 (0) 2 (22) 0 (0) 0 (0)
Hypertension 18 (45) 19 (48) 12 (57) 8 (38)
Dyslipidemia 18 (45) 19 (48) 8 (38) 13 (62)
Family history of coronary artery disease 8 (20) 13 (33) 3 (14) 6 (29)
Current smoker 16 (40) 23 (57) 12 (57) 11 (52)
Peripheral arterial disease 1 (3) 2 (5) 1 (5) 1 (5)
Carotid artery disease 2 (5) 2 (5) 1 (5) 1 (5)
Chronic kidney disease,  estimated glomerular 
filtration rate <60 mL/min
7 (18) 4 (10) 3 (14) 1 (5)
Heart failure 0 (0) 0 (0) 1 (5) 0 (0)
Previous myocardial infarction 6 (15) 6 (15) 2 (10) 2 (10)
Previous percutaneous coronary intervention 6 (15) 6 (15) 2 (10) 1 (5)
Previous coronary artery bypass graft 0 (0) 2 (5) 0 (0) 1 (5)
Previous bleeding requiring medical attention 2 (5) 3 (8) 1 (5) 0 (0)
Chronic obstructive pulmonary disease 4 (10) 4 (10) 0 (0) 3 (14)
Symptom onset to percutaneous coronary intervention, h
  <3 23 (57) 19 (48) 9 (43) 12 (57)
  3 to 6 6 (15) 7 (18) 5 (24) 3 (14)
  >6 11 (28) 14 (35) 7 (33) 6 (29)
Baseline medications
  Aspirin, daily dose ≤100 mg 6 (15) 9 (23) 4 (19) 2 (10)
  Oral anticoagulants 0 (0) 0 (0) 0 (0) 0 (0)
  Statins 10 (25) 10 (25) 4 (19) 5 (24)
  Other lipid-lowering drug 3 (8) 0 (0) 1 (5) 1 (5)
  Angiotensin-converting enzyme inhibitor 5 (13) 9 (23) 1 (5) 1 (5)
  Angiotensin II antagonist 5 (13) 4 (10) 6 (29) 5 (24)
  β-Blocker 7 (18) 8 (20) 3 (14) 2 (10)
  Amiodarone 0 (0) 0 (0) 1 (5) 0 (0)
  Calcium antagonist 5 (13) 6 (15) 3 (14) 2 (10)
  Nitrates 0 (0) 0 (0) 0 (0) 0 (0)
  Diuretics 7 (18) 4 (10) 7 (33) 2 (10)
  Insulin 0 (0) 2 (5) 0 (0) 0 (0)
  Oral antidiabetic 5 (13) 5 (13) 3 (14) 3 (14)
  Nonsteroidal anti-inflammatory drug 2 (5) 2 (5) 0 (0) 1 (5)
  Antidepressant drug 0 (0) 3 (8) 2 (10) 2 (10)
  Proton pump inhibitor 5 (13) 8 (20) 3 (14) 4 (19)
Data are mean±SD or n (%).
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Pharmacokinetic Assessment
Chewed prasugrel, compared with integral prasugrel, 
was associated with higher PAM levels at 15, 30, and 
60 minutes, but not thereafter. Maximum observed 
plasma concentration, time to maximum plasma con-
centration, AUC0 to 2 hours and AUC0 to 4 hours did not dif-
fer between the 2 prasugrel groups. AUC0 to 30 minutes and 
AUC0 to 1 hour were both significantly higher with chewed 
compared with integral prasugrel (Figure 5 and Table 3).
DISCUSSION
To our knowledge, our study is the first to compare 
the pharmacodynamic effects of cangrelor, a direct 
parenteral P2Y12 inhibitor, with tirofiban, a GPI, as well 
as the pharmacodynamic and pharmacokinetic effects 
of a 60-mg chewed or integral pill intake of prasugrel, 
an oral indirect P2Y12 inhibitor. The following are the 
main findings of the study (Figure 6):
• Cangrelor did not reach noninferiority with tiro-
fiban at ADP-induced platelet aggregation; the 
latter showed superior platelet inhibition at 30 
minutes as well as at all other time points.
• Cangrelor and tirofiban provided superior inhibi-
tion of platelet aggregation after ADP compared 
with chewed prasugrel at 30 minutes. Tirofiban 
remained associated with higher inhibition of ADP-
induced platelet aggregation at all time points. 
Table 2. Clinical Presentation and Catheterization Laboratory Data
Variable
Cangrelor 
(n=40)
Tirofiban 
(n=40)
Chewed 
Prasugrel 
(n=21)
Cangrelor vs 
Tirofiban,
P Value
Cangrelor 
vs Chewed 
Prasugrel,  
P Value
Tirofiban 
vs Chewed 
Prasugrel,  
P Value
Integral 
Prasugrel 
(n=21)
Integral 
Prasugrel 
vs Chewed 
Prasugrel,
P Value
Presentation
Systolic arterial pressure, mm Hg 140.0±29.0 141.1±32.9 149.4±27.2 0.877 0.223 0.323 142.2±37.9 0.481
Diastolic arterial pressure, mm Hg 81.5±17.2 83.9±19.8 83.0±13.8 0.555 0.718 0.857 78.7±11.6 0.271
Heart rate, beats/min 76.5±15.9 80.1±16.1 75.9±12.9 0.311 0.893 0.307 73.7±14.3 0.606
Killip class    0.524 0.715 0.569  0.078
  I 28 (70) 26 (65) 16 (76) 0.812 0.766 0.561 20 (95) 0.184
  II 11 (28) 13 (33) 5 (24) 0.808 1.000 0.564 1 (5) 0.184
  III 1 (3) 0 (0) 0 (0) 1.000 1.000  0 (0)  
  IV 0 (0) 1 (3) 0 (0) 1.000  1.000 0 (0)  
Left ventricular ejection fraction, % 46.4±9.1 45.0±9.9 44.7±10.0 0.527 0.524 0.918 48.5±9.7 0.242
Cardiac arrest 1 (3) 3 (8) 0 (0) 0.615 1.000 0.545 1 (5) 1.000
≥2 Episodes of chest pain in the 
past 24 h
13 (33) 12 (30) 7 (33) 1.000 1.000 0.780 6 (29) 1.000
Rhythm    0.122 0.164 0.696  0.311
  Sinus rhythm 40 (100) 36 (90) 20 (95) 0.116 0.344 0.651 21 (100) 1.000
  Atrial fibrillation 0 (0) 3 (8) 1 (5) 0.241 0.344 1.000 0 (0) 1.000
  Other rhythm 0 (0) 1 (3) 0 (0) 1.000 1.000 0 (0)  
Intraventricular conduction defects 3 (8) 7 (18) 2 (10) 0.311 1.000 0.479 2 (10) 1.000
  Left bundle branch block 1 (3) 5 (13) 1 (5) 0.201 1.000 0.654 1 (5) 1.000
  Right bundle branch block 2 (5) 1 (3) 1 (5) 1.000 1.000 1.000 1 (5) 1.000
  Other conduction defect 0 (0) 1 (3) 0 (0) 1.000 1.000 0 (0)  
Vasopressor (continuous infusion) 2 (5) 2 (5) 0 (0) 1.000 0.541 0.541 1 (5) 1.000
Catheterization
  First arterial access    0.762 0.881 0.685  0.679
   Femoral 7 (18) 6 (15) 4 (19) 1.000 1.000 0.725 3 (14) 1.000
   Radial 33 (83) 34 (85) 17 (81) 1.000 1.000 0.725 18 (86) 1.000
  Shift to other access site    0.590 0.691 0.696  1.000
   Not needed 38 (95) 36 (90) 20 (95) 0.675 1.000 0.651 20 (95) 1.000
   To femoral 1 (3) 3 (8) 1 (5) 0.615 1.000 1.000 1 (5) 1.000
   To radial 1 (3) 1 (3) 0 (0) 1.000 1.000 1.000 0 (0)  
Data are expressed as mean±SD (P values from t tests) or n (%; P values from Fisher exact tests or χ2 tests).
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Cangrelor, on the other hand, proved superior to 
chewed prasugrel at ADP-induced platelet aggre-
gation test up to 1 hour from drug administration, 
but it provided similar treatment effect at 2 hours 
and lower IPA at later assessments.
• Chewed prasugrel, compared with integral pra-
sugrel, did not provide greater ADP-induced IPA 
despite providing greater active metabolite bio-
availability up to 1 hour after drug administration.
• TRAP-induced platelet aggregation was pro-
foundly inhibited by tirofiban infusion whereas 
it was mildly affected by cangrelor or chewed or 
integral prasugrel at peak effects (ie, early after 
bolus administration for cangrelor and at 3 hours 
and 4 to 6 hours for both prasugrel arms).
On-treatment residual platelet reactivity measured at the 
time of intervention with LTA in response to ADP or at 
other platelet function assays correlates with myocardial 
damage, ST-segment–elevation resolution, procedural 
success, and clinical outcomes among patients with STE-
MI.24,25 Standard loading dose of newer P2Y12 inhibitors, 
even when administered at first medical contact, pro-
vides only limited IPA at the time of intervention,5,7 which 
led to the investigation of alternative treatment strate-
gies aiming at enhancing early suppression of platelet 
reactivity, procedural success, and potentially improved 
outcomes among patients with STEMI.
Numerous studies have formed the basis for the 
currently approved cangrelor regimen.12,13 Yet, none 
of them included patients with STEMI and the ma-
jority of them evaluated multiple maintenance can-
grelor regimens administered for several hours while 
omitting an initial bolus regimen. Among 14 patients 
with unstable angina or non–Q-wave MI, treated with 
aspirin, UFH, and cangrelor infusion at 4 μg/kg/min 
for up to 69 hours, mean IPA was 98.7±2.1% at 24 
Figure 2. Pharmacodynamic effects of drugs measured by LTA after ADP 20 µmol/L stimulation.
A, Percentage of inhibition of platelet aggregation (IPA). B, IPA >80%. C, IPA >90%. ADP indicates adenosine diphosphate; CI, confidence interval; LS, least 
square; and LTA, light transmittance aggregometry.
Figure 3. Rates of high residual platelet reactivity defined by platelet aggregation >59% at LTA after ADP 20 µmol/L stimulation.
°P<0.001 versus cP; *P<0.001 versus C and cP; **P<0.05 versus cP; #P<0.001 versus C; §P<0.05 versus cP; ¶P<0.01 versus C. ADP indicates adenosine diphos-
phate; and LTA, light transmittance aggregometry.
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hours measured through whole blood impedance ag-
gregometry and using ADP 3 μmol/L as agonist.26 In 
another randomized trial (composed of 2 parts) in-
cluding overall 399 patients undergoing elective or 
urgent PCI, but excluding patients with STEMI, the 
mean %IPA measured with impedance aggregometry 
in heparinized blood in response to ADP 3 μmol/L was 
99% for those receiving cangrelor infusion at 4 μg/
kg/min.27 During part 2, the mean platelet inhibition 
was 100% before the end of infusion for both can-
grelor 4 μg/kg/min and abciximab groups with 95% 
and 100% of patients achieving 100% platelet inhibi-
tion, respectively.27
Across these pivotal dose-finding studies, response 
to 3 μmol/L of ADP was chosen because this concentra-
tion was found to produce maximal or just submaximal 
activation when testing with impedance aggregometry 
in heparinized blood and a degree of activation similar 
to that seen with 5 to 20 μmol/L of ADP when using 
optical aggregometry in citrated platelet-rich plasma.27
We therefore anticipated a nearly maximal IPA in re-
sponse to 20 μmol/L of ADP at optical aggregometry in 
citrated platelet-rich plasma and powered the study for 
noninferiority based on a stringent noninferiority mar-
gin. Our findings show that cangrelor provides a quicker 
onset of action among patients with STEMI as compared 
with prasugrel, administered with either chewed or inte-
gral pill loading dose. Yet, cangrelor yielded lower than 
expected and inferior IPA than tirofiban throughout the 
study duration as well as than prasugrel at 3 hours or 4 
to 6 hours after drug administration. This latter finding 
likely reflects the fast recovery of platelet function at the 
end of cangrelor infusion and the time needed for pra-
sugrel to provide sufficient IPA once cangrelor infusion is 
terminated. IPA in response to 5 or 20 µmol/L ADP was 
lower with cangrelor during drug infusion as compared 
with prasugrel peak effect at 3 hours or 4 to 6 hours. 
Patients with STEMI have higher platelet reactivity,28 
have higher expression of P2Y12 receptor,
29 and require 
greater concentration of antiplatelet agents to achieve 
similar IPA as compared with healthy subjects or patients 
without ongoing myocardial ischemia undergoing elec-
tive coronary artery disease.30 It was previously observed 
that, among patients with type 2 diabetes mellitus, in 
whom enhanced platelet P2Y12 receptor expression oc-
curs, cangrelor yields lower IPA compared with nondia-
betic patients.31 Whether an increased cangrelor regi-
men is required to yield greater IPA among STEMI, and 
in a similar order of magnitude as previously observed 
in patients undergoing elective procedures, remains 
speculative. The CANTIC study (Cangrelor and Crushed 
Ticagrelor in STEMI Patients Undergoing Primary Per-
cutaneous Coronary Intervention) assessed pharmaco-
dynamic effects of standard cangrelor regimen versus 
placebo as P2Y12 reaction units (PRUs) by VerifyNow 
and platelet reactivity index by vasodilator-stimulated 
Figure 4. Pharmacodynamic effects of drugs measured by LTA.
Pharmacodynamic effects of drugs measured by LTA after stimulation with ADP 5 µmol/L (A) and TRAP 15 (B) and 5 (C) µmol/L. ADP indicates adenosine di-
phosphate; CI, confidence interval; IPA, inhibition of platelet aggregation; LS, least square; LTA, light transmittance aggregometry; and TRAP, thrombin receptor 
agonist peptide.
Figure 5. Pharmacokinetic analysis comparing PAM concentrations 
between chewed and integral prasugrel groups.
CI indicates confidence interval; and PAM, prasugrel active metabolite.
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phosphoprotein in patients with STEMI undergoing PCI 
concomitantly treated with crushed ticagrelor.32 In the 
cangrelor plus ticagrelor arm, median PRU value was 63, 
with an interquartile range of 32 to 93. No patient with 
cangrelor had a PRU higher than 208 U during drug 
infusion. Yet, this cutoff value for defining nonrespon-
siveness to P2Y12 inhibitors was generated for the pre-
diction of out-of-hospital events among patients who 
underwent elective PCI and it remains unclear whether 
it applies to patients with STEMI undergoing emergency 
treatment.33 It is interesting that 3 out of 22 patients 
remained nonresponders to cangrelor at vasodilator-
stimulated phosphoprotein assay during drug infusion.32 
Alexopoulos et al34 reported that HRPR was 6.7% at 15 
minutes and 0% at 1 hour (using VerifyNow and a cut-
off of PRU >208) in 15 patients with STEMI receiving 
cangrelor (pretreated with ticagrelor; none of them re-
ceived morphine). Ubaid et al35 reported an HRPR rate 
of 10% (using VerifyNow and a cutoff of PRU >208) 
at the time of balloon inflation in 50 cangrelor-treated 
patients with STEMI. In Buchtele et al,36 16 cardiac ar-
rest survivors with STEMI, who were treated with tar-
geted temperature management, received cangrelor, 
and none had HRPR (using Multiplate Analyzer, platelet 
function had a median 18 U, interquartile range 10 to 
25; <46 U was used as the cutoff). Our results show 
a much higher rate of HRPR during cangrelor infusion 
(50% to 58%) at LTA test after 20 µmol/L ADP stimula-
tion, whereas HRPR ranged from 8.6% at 15 minutes 
to ≈14% at 30 minutes and 2 hours at Multiplate test-
ing. Therefore, whereas the rates of HRPR varied across 
STEMI studies, most likely reflecting different platelet 
function tests and test-specific HRPR cutoffs, almost all 
STEMI studies have identified some degree of hypore-
sponsiveness to cangrelor.
Unlike cangrelor and prasugrel, tirofiban exerts a 
downstream IPA by blocking the glycoprotein IIb/IIIa re-
ceptor. This explains our observations on TRAP-induced 
platelet aggregation, which was profoundly inhibited 
by tirofiban but not with cangrelor or prasugrel. In 
keeping with previous observations,7 our results con-
firm that P2Y12 inhibition exerts a mild yet measurable 
effect on TRAP-induced platelet aggregation.
A strategy to crush a standard loading dose of ticagre-
lor or prasugrel has resulted in greater drug bioavailability 
and higher IPA in the first few hours after drug adminis-
tration compared with whole tablets in patients with STE-
MI.11,13 However, crushing tablets requires available dedi-
cated point-of-care devices. Recently, chewed ticagrelor 
resulted in a more rapid platelet inhibition compared 
with crushed or whole tablets among patients undergo-
ing coronary angiography for stable angina.10 No study 
had so far examined whether chewed prasugrel increases 
PAM bioavailability and allows a more rapid IPA among 
patients with STEMI. In our study, chewed compared with 
integral prasugrel was associated with higher PAM levels 
up to 1 hour after drug administration. Despite numeric 
higher IPA with chewed prasugrel, at no time point was 
IPA significantly greater than integral prasugrel at LTA 
measurements. At Multiplate testing, IPA was greater 
with chewed as compared with integral prasugrel at 30 
and 60 minutes. Yet, this assay was performed in only 2 
out of 3 centers participating in the study and thus was 
available in a subset of patients (n=108).
Our results are consistent with previous observa-
tions suggesting that crumbling P2Y12 inhibitor tablets 
Table 3. Pharmacokinetic Analysis Comparing Prasugrel Active Metabolite Concentrations Between Chewed and Integral Prasugrel Groups
Prasugrel Active Metabolite Chewed Prasugrel (n=17) Integral Prasugrel (n=15)
Chewed Prasugrel vs 
Integral Prasugrel Least 
Square Mean Difference or 
Mean Difference (95% CI)
Integral Prasugrel vs 
Chewed Prasugrel,  
P Value
Baseline 0.000±0.000 0.000±0.000   
15 min 51.066±79.488 2.184±5.252 48.9 (12.1 to 85.7) 0.009
30 min 62.289±82.626 17.052±43.453 45.2 (8.4 to 82.1) 0.016
1 h 68.836±87.797 27.861±52.841 41.0 (4.2 to 77.8) 0.029
2 h 23.518±25.491 59.164±72.739 −35.6 (−72.5 to 1.2) 0.058
3 h 8.446±9.127 39.544±55.248 −31.1 (−67.9 to 5.7) 0.098
4 to 6 h 7.582±20.270 14.208±14.777 −5.7 (−43.0 to 31.6) 0.766
Tmax 1.441±1.316 1.933±1.033 −0.5 (−1.3 to 0.3) 0.244
Cmax 98.795±86.493 94.634±79.108 4.2 (−53.6 to 61.9) 0.888
AUC0 to 4 h 124.787±117.474 136.219±104.129 −11.4 (−88.8 to 65.9) 0.772
AUC0 to 2 h 101.286±112.093 60.029±68.782 41.3 (−24.3 to 106.8) 0.217
AUC0 to 1 h 55.106±67.246 16.525±33.094 38.6 (1.0 to 76.1) 0.044
AUC0 to 30 min 9.214±13.664 0.758±1.341 8.5 (1.5 to 15.4) 0.017
Data are expressed as least square mean±SD (P values from mixed models) for 15 min to 4 to 6 h (in ng/mL) and mean±SD for time for the maximum plasma 
concentration (Tmax), maximum observed plasma concentration (Cmax; in ng/mL), and area under the plasma concentration vs time curve (AUC) mean units (P 
values from separate general linear models). In 1 patient randomized to chewed prasugrel, the assessment at 4 to 6 h was not available.
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increases early drug availability. However, in the setting 
of our multicenter study, chewed tablets resulted in 
only a mild and lower than anticipated IPA increase in 
the first hour after drug administration.
Our study might have important clinical implications. 
First, the comparative efficacy data of intravenous agents 
with chewed prasugrel reinforces the superiority notion 
of parenteral over oral antiplatelet medications in the 
acute phase of STEMI treatment. Second, among paren-
teral drugs, tirofiban demonstrated superior efficacy than 
cangrelor, which in turn was associated with relatively 
high HRPR rates, suggesting that GPI might be prefer-
able over cangrelor to minimize the risk of acute ischemic 
complications. A recent large retrospective study sug-
gested that a short regimen of GPI was protective against 
stent thrombosis risk in morphine-treated patients with 
STEMI (who are potentially exposed to increased risk of 
acute stent thrombosis owing to delayed absorption of 
oral P2Y12 inhibitors).
37 In recent years, the use of GPI has 
declined, mainly because of the perception that the isch-
emic benefits are counterbalanced by bleeding risks.3 Yet, 
clinical data on GPI are mainly based on prolonged post-
bolus drug infusion and femoral access site at the time 
of intervention. Large-scale trials reassessing the com-
parative risks and benefits of short infusion of parenteral 
platelet inhibitors such as cangrelor or GPI compared with 
newer oral P2Y12 receptor blockers alone in contempo-
rary primary PCI practice remain desirable.
Limitations
Our study was mechanistic in nature and was not pow-
ered for clinical end points. Whereas multiple prior studies 
have shown an association between low residual platelet 
Figure 6. Pharmacodynamic and pharmacokinetic effects of cangrelor, tirofiban, and prasugrel (chewed or integral) in patients with ST-segment–
elevation myocardial infarction undergoing primary percutaneous coronary intervention 30 minutes after drug administration.
ADP indicates adenosine diphosphate; and TRAP, thrombin receptor agonist peptide. 
Gargiulo et al The FABOLUS-FASTER Trial
August 4, 2020 Circulation. 2020;142:441–454. DOI: 10.1161/CIRCULATIONAHA.120.046928452
OR
IG
IN
AL
 R
ES
EA
RC
H 
AR
TI
CL
E
reactivity and better ischemic outcomes during and after 
PCI among patients undergoing elective procedures as 
well as patients with STEMI, the comparative efficacy and 
safety profile of cangrelor, tirofiban, or prasugrel in pa-
tients undergoing primary PCI remain to be established in 
an adequately powered clinical trial. A single study has sug-
gested that prasugrel can be given at the start of cangre-
lor infusion, without evidence of drug–drug interaction.38 
Whether this evidence applies to patients with STEMI is 
unknown and this treatment strategy remains off-label. 
Applicability to ticagrelor loading, which is mostly used in 
clinical practice at the beginning of cangrelor infusion or 
before primary PCI,39,40 cannot be claimed. However, on 
the basis of our observation that cangrelor followed by 
prasugrel associates with a rebound of platelet activation 
at 2 to 4 hours and on previous data showing some HRPR 
during and after cangrelor infusion,32,34 one could specu-
late that when cangrelor is used, ticagrelor might be the 
preferred oral P2Y12 inhibitor. It remains unclear whether 
the test-specific cutoffs used to define HRPR rates retain 
prognostic implications for the acute treatment of STEMI, 
considering that they were generated mainly for stable or 
stabilized patients receiving oral P2Y12 inhibitors.
Conclusions
Among patients with STEMI undergoing primary PCI, 
cangrelor provided inferior IPA compared with tirofi-
ban; both parenteral treatment strategies yielded su-
perior IPA during drug infusion compared with chewed 
prasugrel, which, despite achieving early higher active 
metabolite concentrations, did not lead to greater IPA 
compared with integral prasugrel.
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